Alexander Colevas

Clinical Trials

• Recruiting Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
• Recruiting A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
• Not Recruiting Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
• Not Recruiting Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
• Recruiting Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
• Recruiting Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)
• Recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
• Recruiting Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
• Recruiting Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
• Not Recruiting Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
• Recruiting Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
• Not Recruiting AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
• Not Recruiting Phase III Randomized, Placebo Controlled, Trial Of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib, NSC 715055) In Performance Status 2 Or Previously Treated Patients With Recurrent Or Metastatic Head And Neck Cancer
• Not Recruiting A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
• Not Recruiting A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
• Not Recruiting Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
• Not Recruiting PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer
• Not Recruiting An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed
• Not Recruiting A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma
• Not Recruiting Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
• Not Recruiting Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
• Not Recruiting A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
• Not Recruiting A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
• Not Recruiting A Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-Sponsored Phase I or II Cancer Study
• Not Recruiting An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
• Not Recruiting An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
• Not Recruiting Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
• Not Recruiting Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
• Not Recruiting Paclitaxel, Cisplatin, and Cetuximab Followed By Cetuximab and Intensity-Modulated Radiation Therapy in Treating Patients With HPV-Associated Stage III or Stage IV Cancer of the Oropharynx That Can Be Removed By Surgery
• Not Recruiting A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
• Not Recruiting A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer
• Not Recruiting Phase II Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
• Not Recruiting BIBW 2992 (Afatinib) in Head & Neck Cancer
• Not Recruiting Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
• Not Recruiting A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer NSCLC.
• Not Recruiting A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors
• Not Recruiting Phase 1 Trial of Oral Ixabepilone
• Not Recruiting Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study
• Not Recruiting Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
• Recruiting Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• Recruiting A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
• Recruiting A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
• Recruiting 4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy
• Not Recruiting Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
• Recruiting Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
• Recruiting Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers